Robert F. Kennedy Jr.'s newly appointed Advisory Committee on Immunization Practices (ACIP) has significantly altered the landscape of COVID-19 vaccine recommendations in the United States. Instead of recommending universal vaccination for all individuals over six months of age, the panel now advocates for a model of 'shared clinical decision-making.' This approach emphasizes consultations between healthcare providers and patients, allowing for individualized assessments of risk and benefit.
This shift marks a departure from previous years, where the ACIP had recommended universal COVID-19 vaccination for the same age group. The change is unsurprising, considering Kennedy replaced all previous members of the ACIP with individuals known for their skepticism towards mRNA COVID-19 vaccines. The ACIP's recommendations influence vaccine coverage under insurance policies, adding a layer of complexity to the existing public health strategy.
The altered recommendations have sparked concern among public health experts. They argue that shifting away from a universal recommendation, particularly for children and healthy adults, could hinder vaccine access, especially in rural areas where healthcare access might already be limited. This transition could also reduce overall vaccination rates, potentially leading to increased disease transmission.
The CDC, which is yet to adopt the ACIP’s revised recommendations, previously issued universal vaccine guidance that recent studies suggest could prevent thousands of hospitalizations and deaths annually. The panel's decision comes at a time when the FDA has approved new COVID-19 vaccines with restricted eligibility criteria. Several states, in contrast to the new federal guidance, maintain that broader population vaccination is advisable for those seeking protection.
The debate within the workgroup itself highlights the existing divergence in perspectives. While some members, like Dr. Henry Bernstein, cautioned that prescriptions and individualized decisions could create access barriers and emphasized the safety and effectiveness of COVID-19 vaccines, others, including Retsef Levi, expressed reservations about the efficacy and safety of mRNA vaccines and argued for prescription requirements. This internal division underscores the complexity of the ongoing discussion around COVID-19 vaccination policy.
Despite the changes, America's Health Insurance Plans has stated that its member plans will continue to cover all vaccines currently recommended by the ACIP. This decision provides a measure of continuity, guaranteeing coverage for COVID-19 and flu vaccines for over 200 million Americans, regardless of the ACIP's evolving recommendations. The long-term impact of this policy shift and its consequences for public health remain to be seen.
---
Originally published at: https://www.cnbc.com/2025/09/19/rfk-jr-vaccine-panel-covid-shot-recommendations.html
